Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProQR Therapeutics NV

1.81
+0.03001.69%
Pre-market: 1.870.0600+3.31%08:00 EDT
Volume:153.58K
Turnover:280.32K
Market Cap:190.67M
PE:-4.98
High:1.86
Open:1.80
Low:1.80
Close:1.78
Loading ...

Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4

MT Newswires Live
·
10 Mar

ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
07 Mar

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%

Simply Wall St.
·
11 Feb

Oppenheimer Initiates ProQR Therapeutics at Outperform With $15 Price Target

MT Newswires Live
·
10 Jan

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and ProQR (PRQR)

TIPRANKS
·
10 Jan

Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?

Simply Wall St.
·
20 Dec 2024

ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70%

Simply Wall St.
·
14 Dec 2024

ProQR Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Dec 2024

ProQR Therapeutics to Receive $8.1 Million Funding from Rett Syndrome Research

MT Newswires Live
·
11 Dec 2024

ProQR Therapeutics announces $8.1M in new funding from RSRT

TIPRANKS
·
11 Dec 2024

ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand Rna Editing Collaboration

THOMSON REUTERS
·
11 Dec 2024

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

GlobeNewswire
·
11 Dec 2024

ProQR Therapeutics appoints Beal as Chief ADAR Scientist

TIPRANKS
·
10 Dec 2024